-transparent.png){kind=logo}
Ceftazidime is poorly bound to plasma proteins, is not metabolized and is excreted mostly by glomerular filtration. Its elimination half-life is about 1.5-2 hours, and their kinetics are modified by renal impairment. The dosage recommended in adult is 1 to 2 g 8-hourly, to be adjusted to the needs of individual cases. The interval between doses must be extended to 12 hours in patients with mild renal impairment and to 36-48 hours in those with severe renal failure. A supplementary dose of ceftazidime is required at the end of each haemodialysis session. In patients under chronic peritoneal dialysis, the loading dose (10 mg/kg) is followed by continuous administration of 5 mg/kg into each dialysis cavity.
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
May 1983,
The Journal of antimicrobial chemotherapy,
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
May 1988,
Clinical pharmacology and therapeutics,
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
September 1981,
The Journal of antimicrobial chemotherapy,
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
May 1991,
Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
August 1983,
International journal of clinical pharmacology, therapy, and toxicology,
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
March 1981,
Antimicrobial agents and chemotherapy,
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
April 1991,
Journal of clinical pharmacology,
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
January 1982,
Acta medica Scandinavica. Supplementum,
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
September 1981,
The Journal of antimicrobial chemotherapy,
A Leroy, and
J P Fillastre, and
G Humbert, and
F Borsa, and
F Leguy, and
G R Spencer
January 1984,
Arzneimittel-Forschung,
